Mainz Biomed NV- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Mainz Biomed NV 公司

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

Mainz Biomed NV简介



公司代码MYNZ

公司名称Mainz Biomed NV

上市日期Nov 04, 2021

CEOBaechler (Guido)

员工数量19

证券类型Ordinary Share

年结日Nov 04

公司地址Sirius Gutenberg Park

城市MAINZ

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Germany

邮编55129

电话496131265140

网址https://www.mainzbiomed.com/

公司代码MYNZ

上市日期Nov 04, 2021

CEOBaechler (Guido)

Mainz Biomed NV公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Guido Baechler

Chief Executive Officer, Executive Director

20.06K

+1250.00%

Mr. Hans Hekland

Non-Executive Independent Director

17.77K

-151.00%

Dr. Chris von Toerne

Chief Operating Officer

2.50K

+2331.00%

Dr. Heiner Dreismann, Ph.D.

Non-Executive Independent Director

2.20K

--

Mr. William Caragol

Chief Financial Officer

--

Mr. Gregory J. (Greg) Tibbitts

Non-Executive Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Guido Baechler

Chief Executive Officer, Executive Director

20.06K

+1250.00%

Mr. Hans Hekland

Non-Executive Independent Director

17.77K

-151.00%

Dr. Chris von Toerne

Chief Operating Officer

2.50K

+2331.00%

Dr. Heiner Dreismann, Ph.D.

Non-Executive Independent Director

2.20K

--

Mr. William Caragol

Chief Financial Officer

--

Mr. Gregory J. (Greg) Tibbitts

Non-Executive Independent Director

--

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 2月6日周五

持股股东

股东类型

持股股东

占比

Donahue (Kevin Michael)

7.56%

Armistice Capital LLC

4.35%

UBS Financial Services, Inc.

0.60%

Dauntless Investment Group, LLC

0.56%

Fur Wiederaufbau (Kredianstalt)

0.26%

其他

86.67%

持股股东

占比

Donahue (Kevin Michael)

7.56%

Armistice Capital LLC

4.35%

UBS Financial Services, Inc.

0.60%

Dauntless Investment Group, LLC

0.56%

Fur Wiederaufbau (Kredianstalt)

0.26%

其他

86.67%

股东类型

持股股东

占比

Individual Investor

8.38%

Hedge Fund

4.35%

Investment Advisor

1.48%

其他

85.78%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

32

529.62K

5.85%

+130.29K

2025Q3

32

386.03K

7.13%

+144.51K

2025Q2

35

323.69K

7.07%

-4.46K

2025Q1

40

350.55K

9.90%

-3.02K

2024Q4

40

356.23K

16.03%

+257.88K

2024Q3

37

115.45K

5.70%

+19.26K

2024Q2

34

120.95K

9.96%

+24.53K

2024Q1

36

122.04K

10.26%

+25.33K

2023Q4

27

96.56K

23.08%

+9.46K

2023Q3

22

91.42K

24.64%

+4.27K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Armistice Capital LLC

394.52K

4.35%

+109.52K

+38.43%

Sep 30, 2025

UBS Financial Services, Inc.

7.00K

0.08%

-2.81K

-28.64%

Sep 30, 2025

Dauntless Investment Group, LLC

51.00K

0.56%

+1.00K

+2.00%

Sep 30, 2025

Fur Wiederaufbau (Kredianstalt)

23.20K

0.26%

-7.74K

-25.00%

Sep 30, 2024

Baechler (Guido)

20.06K

0.22%

+1.25K

+6.65%

Mar 21, 2025

Hekland (Hans)

17.77K

0.2%

-151.00

-0.84%

Mar 21, 2025

Journey Advisory Group, LLC

15.00K

0.17%

--

Sep 30, 2025

Steward Partners Investment Advisory, LLC

10.00K

0.11%

--

Sep 30, 2025

Caragol (William J)

7.90K

0.09%

+2.58K

+48.56%

Mar 21, 2025

持股ETF



机构名称

占比

暂无数据

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

除权除息日

类型

比率

Nov 29, 2024

Merger

40→1

Nov 29, 2024

Merger

40→1

Nov 29, 2024

Merger

40→1

Nov 29, 2024

Merger

40→1

公告日期

除权除息日

类型

比率

Nov 29, 2024

Merger

40→1

Nov 29, 2024

Merger

40→1

Nov 29, 2024

Merger

40→1

Nov 29, 2024

Merger

40→1